Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMC Res Notes ; 5: 684, 2012 Dec 13.
Artigo em Inglês | MEDLINE | ID: mdl-23237104

RESUMO

BACKGROUND: Benzodiazepine (BZD), the long-term treatment of which is harmful for cognitive function, is widely prescribed by General Practitioners in Spain. Based on studies performed in other countries we designed a nurse-led BZD withdrawal program adapted to Spanish Primary Care working conditions. RESULTS: A pseudo-experimental (before-after) study took place in two Primary Care Centres in Barcelona. From a sample of 1150 patients, 79 were identified. They were over 44 years old and had been daily users of BZD for a period exceeding six months. Out of the target group 51 patients agreed to participate. BZD dosage was reduced every 2-4 weeks by 25% of the initial dose with the optional support of Hydroxyzine or Valerian. The rating measurements were: reduction of BZD prescription, demographic variables, the Short-Form Health Survey (SF-12) to measure quality of life, the Medical Outcomes Study (MOS) Sleep Scale, and the Goldberg Depression and Anxiety Scale.By the end of the six-month intervention, 80.4% of the patients had discontinued BZD and 64% maintained abstinence at one year. An improvement in all parameters of the Goldberg scale (p <0.05) and in the mental component of SF-12 at 3.3 points (p = 0.024), as well as in most components of the MOS scale, was observed in the group that had discontinued BZD. No significant differences in these scales before and after the intervention were observed in the group that had not discontinued. CONCLUSIONS: At one year approximately 2/3 of the patients had ceased taking BZD. They showed an overall improvement in depression and anxiety scales, and in the mental component of the quality of life scale. There was no apparent reduction in the sleep quality indicators in most of the analysed components. Nurses in a Primary Care setting can successfully implement a BZD withdrawal program.


Assuntos
Antidepressivos/efeitos adversos , Ansiedade/tratamento farmacológico , Benzodiazepinas/efeitos adversos , Transtorno Depressivo/tratamento farmacológico , Profissionais de Enfermagem/organização & administração , Atenção Primária à Saúde , Adulto , Ansiedade/fisiopatologia , Transtorno Depressivo/fisiopatologia , Esquema de Medicação , Feminino , Humanos , Hidroxizina/farmacologia , Hidroxizina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Extratos Vegetais/farmacologia , Extratos Vegetais/uso terapêutico , Qualidade de Vida , Projetos de Pesquisa , Retirada de Medicamento Baseada em Segurança , Sono/efeitos dos fármacos , Espanha , Inquéritos e Questionários , Valeriana/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...